Optimal Pair Matching Combined with Machine Learning Predicts that Omega-3 Fatty Acid Supplementation Markedly Reduces the Risk of Myocardial Infarction in African Americans

Shudong Sun,Aki Hara,Laurel Johnstone,Brian Hallmark,Eric Lu,Joseph C. Watkins,Cynthia A. Thomson,Susan M. Schembre,Susan Sergeant,Jason Umans,Guang Yao,Hao Helen Zhang,Floyd H. Chilton

DOI: https://doi.org/10.1101/2024.03.26.24304910

2024-03-28

Abstract:Conflicting results from clinical trials have contributed to a lack of consensus about cardioprotective effects of omega-3 (n-3) highly unsaturated fatty acids (HUFA). Although the VITAL trial did not demonstrate an overall benefit of n-3 HUFA supplementation on composite cardiovascular disease (CVD) and cancer outcomes, the substantial enrollment of African Americans (AfAm) afforded a unique opportunity for a post-hoc analysis of racial differences in the supplementation response. We employed propensity score matching to address potential covariate imbalances between AfAm and European American (EuAm) participants in VITAL (N=3,766 participants). Using Kaplan-Meier curves and two machine learning methodologies, we found that n-3 HUFA supplementation was significantly associated with a reduced risk of myocardial infarction (MI) exclusively in the AfAm subgroup, as evidenced by an odds ratio of 0.17 (95% CI [0.048, 0.59]). These findings indicate a potential cardioprotective benefit of n-3 supplementation in AfAm, specifically in reducing MI risks; a risk not identified in EuAm. Further investigation of n-3 HUFA effects through a hypothesis-driven randomized clinical trial among AfAm is needed to test a race-specific response that may inform recommendations for n-3 HUFA supplementation.

Cardiovascular Medicine

What problem does this paper attempt to address?

This paper examines the potential effects of Omega-3 polyunsaturated fatty acid supplements on reducing the risk of myocardial infarction in African Americans (AfAm). The study analyzed data from the VITAL trial, which involved a large number of African American and European American participants, using a combination of optimal matching and machine learning methods. While the VITAL trial did not show overall benefits of Omega-3 supplementation for cardiovascular disease and cancer, a post-hoc analysis of racial differences revealed a significant association between Omega-3 supplementation and a reduced risk of myocardial infarction in African Americans, with a risk ratio of 0.17 (95% confidence interval [0.048, 0.59]). This suggests that Omega-3 supplementation targeted towards African Americans may have specific cardiac protective effects, particularly in lowering the risk of myocardial infarction. The paper highlights the need for further randomized clinical trials to validate this race-specific response and guide the recommended use of Omega-3 supplements.